Principal Securities, Inc. Mereo Biopharma Group PLC Transaction History
Principal Securities, Inc.
- $5.32 Trillion
- Q2 2025
A detailed history of Principal Securities, Inc. transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Principal Securities, Inc. holds 75 shares of MREO stock, worth $147. This represents 0.0% of its overall portfolio holdings.
Number of Shares
75
Previous 32
134.38%
Holding current value
$147
Previous $112,000
81.25%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding MREO
# of Institutions
99Shares Held
98.2MCall Options Held
2.28MPut Options Held
761K-
Janus Henderson Group PLC London, X017.7MShares$34.7 Million0.02% of portfolio
-
Rubric Capital Management LP New York, NY15.3MShares$30 Million0.96% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA9.44MShares$18.5 Million1.35% of portfolio
-
Mangrove Partners New York, NY8.64MShares$16.9 Million3.39% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.71MShares$13.2 Million0.42% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $245M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...